Morgan Stanley’s Guardion Health Sciences, Inc. Common Stock GHSI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-559
| Closed | -$3.1K | – | 8220 |
|
|
2024
Q3 | $3.1K | Sell |
559
-100
| -15% | -$1.01K | ﹤0.01% | 7035 |
|
|
2024
Q2 | $6.61K | Hold |
659
| – | – | ﹤0.01% | 6784 |
|
|
2024
Q1 | $5.95K | Sell |
659
-659
| -50% | -$4.87K | ﹤0.01% | 6846 |
|
|
2023
Q4 | $7.04K | Buy |
1,318
+659
| +100% | +$4.01K | ﹤0.01% | 6920 |
|
|
2023
Q3 | $4.86K | Hold |
659
| – | – | ﹤0.01% | 6921 |
|
|
2023
Q2 | $5.13K | Hold |
659
| – | – | ﹤0.01% | 6983 |
|
|
2023
Q1 | $4.03K | Sell |
659
-4
| -0.6% | -$27 | ﹤0.01% | 7104 |
|
|
2022
Q4 | $4.81K | Buy |
663
+284
| +75% | +$2.27K | ﹤0.01% | 7160 |
|
|
2022
Q3 | $3K | Buy |
379
+4
| +1% | +$30 | ﹤0.01% | 7410 |
|
|
2022
Q2 | $3K | Sell |
375
-1
| -0.3% | -$9 | ﹤0.01% | 7538 |
|
|
2022
Q1 | $4K | Sell |
376
-1,187
| -76% | -$24.1K | ﹤0.01% | 7650 |
|
|
2021
Q4 | $51K | Sell |
1,563
-4,011
| -72% | -$215K | ﹤0.01% | 6801 |
|
|
2021
Q3 | $354K | Sell |
5,574
-966
| -15% | -$64.2K | ﹤0.01% | 5692 |
|
|
2021
Q2 | $575K | Buy |
6,540
+6,270
| +2,322% | +$545K | ﹤0.01% | 5443 |
|
|
2021
Q1 | $32K | Buy |
270
+156
| +137% | +$31.5K | ﹤0.01% | 6557 |
|
|
2020
Q4 | $14K | Hold |
114
| – | – | ﹤0.01% | 6552 |
|
|
2020
Q3 | $7K | Hold |
114
| – | – | ﹤0.01% | 6380 |
|
|
2020
Q2 | $15K | Buy |
+114
| New | +$15.9K | ﹤0.01% | 6067 |
|
Morgan Stanley's GHSI Position: Q4 2024 in Review
Morgan Stanley sold out of Guardion Health Sciences, Inc. Common Stock (GHSI) in Q4 2024, closing a stake of 559 shares — an estimated $3.1K sold.
Morgan Stanley first reported a position in GHSI in Q2 2020 and held it in 18 quarters. The position peaked at $575K in Q2 2021. 0 funds tracked by Wall St. Rank hold GHSI as of Q4 2024.
- Morgan Stanley reported no remaining Guardion Health Sciences, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Morgan Stanley sold 559 Guardion Health Sciences, Inc. Common Stock shares in Q4 2024, an estimated $3.1K.
- Morgan Stanley first reported a position in Guardion Health Sciences, Inc. Common Stock in Q2 2020 and held it in 18 quarters.
- Morgan Stanley's Guardion Health Sciences, Inc. Common Stock position peaked at $575K in Q2 2021.
- 0 funds tracked by Wall St. Rank held Guardion Health Sciences, Inc. Common Stock as of Q4 2024.
Based on Morgan Stanley's 13F filing for Q4 2024, filed 14 Feb 2025.